ClinicalTrials.gg
CompletedNCT00523549Updated Apr 23, 2012Results posted

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

A Phase 4 interventional study of valsartan and amlodipine in Hypertension and Diastolic Dysfunction, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-04-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
229
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
65th of 139
229 · median 198
Started
2006
with 22 others
Phase 4
67 of 140
none open now
Registered
84th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 65th largest by enrollment of the 139 interventional ones that give a count, is one of 23 that started in 2006, is one of 67 in phase 4, and was the 84th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

The purpose of this study is to determine the effects of treatment with valsartan + amlodipine to a target systolic blood pressure (SBP)\<130 mmHg compared to the Joint National Commission on the Treatment of Hypertension 7 recommended target SBP of \<140 mmHg on the intrinsic diastolic properties of the myocardium in patients with hypertension and echocardiographic evidence of diastolic dysfunction.

03

Conditions studied

  • Hypertension
  • Diastolic Dysfunction

Browse trials for

Keywords

  • Hypertension
  • systolic blood pressure
  • diastolic dysfunction
  • valsartan
  • amlodipine
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 45 years or older
  • Male and female patients are eligible. Female patients must be for one year, surgically sterile, or using effective methods such as a double barrier method with spermicide, an intra-uterine device, or hormonal contraceptives. Post-menopausal women on a stable dose of hormone replacement therapy (HRT) for at least three (3) months prior to the screening visit are eligible for the study.
  • Uncontrolled systolic hypertension on a maximum of two (2) antihypertensive medications at the time of screening.
  • Echocardiographic ≥50% and evidence of diastolic dysfunction.
  • Provide written to participate in the study prior to any screening or study procedures
  • Have the ability to communicate well and comply with all study requirements

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension defined as a MSSBP >200 mmHg and/or MSDBP >120 mmHg.
  • History of a secondary cause of hypertension including but not limited to: coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.
  • \<50 %
  • History of stroke, , myocardial infarction, coronary artery bypass graft surgery, or unstable angina pectoris within 6 months of screening
  • Presence of ventricular or supraventricular arrhythmias (e.g. atrial fibrillation/flutter)
  • History of congestive heart failure
  • History of diabetes mellitus
  • History of renal impairment with serum creatinine >2.0 mg/dL at screening, history of dialysis, or history of nephritic syndrome
  • Antihypertensive therapy with three (3) or more medications at the time of screening
  • Active and/or treated of any organ system within twelve (12) months of enrollment, with the exception of localized basal cell carcinoma of the skin
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>5 mIU/ml)
  • Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they meet the following definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy OR are using one or more of the following acceptable methods of : barrier method with spermicidal agent, an intrauterine device, hormonal contraceptives, or total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception should be maintained throughout the study
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug including, but not limited to, any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active, or active inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator
  • Pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury within 12 months prior to Visit 1
  • Any serum or ALT elevation two (2) times the

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
229 participants (actual)

Study arms

  • Experimental
    Standard treatment regimen

    (Valsartan + Amlodipine to target SBP of \< 140 mmHg)

    Drug: valsartan · Drug: amlodipine

  • Experimental
    Intensive treatment regimen

    (Valsartan + Amlodipine to target SBP \< 130 mm Hg)

    Drug: valsartan · Drug: amlodipine

Interventions

  • 160 mg or 320 mg tablets once a day

    Also known as: Diovan

  • 5 mg or 10 mg tablets once a day

    Also known as: Norvasc

06

What researchers measure

Primary outcomes

  1. Change in Lateral Mitral Annular Myocardial Relaxation Velocity

    Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24

    Time frame: Baseline to 24 weeks after treatment

Secondary outcomes

  1. Change in Left Atrial Size

    Change from baseline in left atrial size at Week 24

    Time frame: Baseline to 24 weeks after treatment

  2. Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity

    Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24

    Time frame: Baseline to 24 weeks after treatment

  3. Percent Change From Baseline in Vascular Stiffness

    Percent change from baseline in Vascular Stiffness (measured by radial augmentation index \[AI\]) at Weeks 8 and 24

    Time frame: Baseline to 8 and 24 weeks after treatment

  4. Change in Mean Sitting Systolic Blood Pressure (msSBP)

    Change from baseline in msSBP at Weeks 8 and 24

    Time frame: Baseline to 8 and 24 weeks after treatment

  5. Change in Mean Sitting Diastolic Blood Pressure (msDBP)

    Change from baseline in msDBP at Weeks 8 and 24

    Time frame: Baseline to 8 and 24 weeks after treatment

  6. Change in Estimated Central Aortic Pressure

    Change from baseline in estimated central aortic pressure at Weeks 8 and 24

    Time frame: Baseline to 8 and 24 weeks after treatment

07

Results

Posted Mar 10, 2011

Participant flow

Participant flow — Overall Study
MilestoneIntensive Treatment RegimenStandard Treatment Regimen
Started114115
Completed9599
Not completed1916
Withdrew: Adverse event63
Withdrew: Unsatisfactory therapeutic effect01
Withdrew: Protocol deviation31
Withdrew: Patient withdrew consent76
Withdrew: Lost to follow-up35

Outcome measures

PrimaryChange in Lateral Mitral Annular Myocardial Relaxation Velocity

Change from baseline in lateral mitral annular myocardial relaxation velocity (E') at Week 24

Time frame:
Baseline to 24 weeks after treatment
Reported as:
Mean · cm/s
Change in Lateral Mitral Annular Myocardial Relaxation Velocity
cm/sIntensive Treatment RegimenStandard Treatment Regimen
Change in Lateral Mitral Annular Myocardial Relaxation Velocity1.544 ± 1.39461.476 ± 1.5985
SecondaryChange in Left Atrial Size

Change from baseline in left atrial size at Week 24

Time frame:
Baseline to 24 weeks after treatment
Reported as:
Mean · cm
Change in Left Atrial Size
cmIntensive Treatment RegimenStandard Treatment Regimen
Change in Left Atrial Size-0.127 ± 0.3082-0.104 ± 0.2845
SecondaryChange in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity

Change from baseline in peak E-wave velocity / lateral mitral annular myocardial relaxation velocity (E/E') at Week 24

Time frame:
Baseline to 24 weeks after treatment
Reported as:
Mean · ratio
Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity
ratioIntensive Treatment RegimenStandard Treatment Regimen
Change in Ratio of Peak E Wave Velocity/Lateral Mitral Annular Myocardial Relaxation Velocity-0.951 ± 2.1729-0.680 ± 2.0714
SecondaryPercent Change From Baseline in Vascular Stiffness

Percent change from baseline in Vascular Stiffness (measured by radial augmentation index \[AI\]) at Weeks 8 and 24

Time frame:
Baseline to 8 and 24 weeks after treatment
Reported as:
Mean · percentage of change in mean AI
Percent Change From Baseline in Vascular Stiffness
percentage of change in mean AIIntensive Treatment RegimenStandard Treatment Regimen
Week 8-7.89 ± 9.645-7.32 ± 11.970
Week 24-6.07 ± 10.582-5.63 ± 11.367
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP)

Change from baseline in msSBP at Weeks 8 and 24

Time frame:
Baseline to 8 and 24 weeks after treatment
Reported as:
Mean · mm Hg
Change in Mean Sitting Systolic Blood Pressure (msSBP)
mm HgIntensive Treatment RegimenStandard Treatment Regimen
Week 8-25.74 ± 16.112-22.31 ± 16.014
Week 24-30.37 ± 18.745-25.06 ± 17.074
SecondaryChange in Mean Sitting Diastolic Blood Pressure (msDBP)

Change from baseline in msDBP at Weeks 8 and 24

Time frame:
Baseline to 8 and 24 weeks after treatment
Reported as:
Mean · mm Hg
Change in Mean Sitting Diastolic Blood Pressure (msDBP)
mm HgIntensive Treatment RegimenStandard Treatment Regimen
Week 8-12.77 ± 10.118-12.62 ± 10.475
Week 24-15.21 ± 10.147-14.08 ± 11.163
SecondaryChange in Estimated Central Aortic Pressure

Change from baseline in estimated central aortic pressure at Weeks 8 and 24

Time frame:
Baseline to 8 and 24 weeks after treatment
Reported as:
Mean · mm Hg
Change in Estimated Central Aortic Pressure
mm HgIntensive Treatment RegimenStandard Treatment Regimen
Week 8-16.30 ± 12.483-14.68 ± 12.751
Week 24-17.71 ± 14.635-14.76 ± 12.689

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intensive Treatment Regimen—3/114 (2.6%)49/114 (43%)
Standard Treatment Regimen—3/114 (2.6%)41/114 (36%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventIntensive Treatment RegimenStandard Treatment Regimen
Atrial fibrillationCardiac disorders1/1140/114
GoitreEndocrine disorders1/1140/114
Appendicitis perforatedGastrointestinal disorders0/1141/114
Intestinal obstructionGastrointestinal disorders0/1141/114
PancreatitisGastrointestinal disorders0/1141/114
Cholecystitis acuteHepatobiliary disorders0/1141/114
Abdominal abscessInfections and infestations0/1141/114
PneumoniaInfections and infestations0/1141/114
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1140/114
Thyroid adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1140/114
Most frequent other events
Most frequent other events
EventIntensive Treatment RegimenStandard Treatment Regimen
Oedema peripheralGeneral disorders24/11420/114
DizzinessNervous system disorders16/1149/114
FatigueGeneral disorders12/1147/114
Upper respiratory tract infectionInfections and infestations8/1147/114
HeadacheNervous system disorders5/1148/114
Muscle spasmsMusculoskeletal and connective tissue disorders6/1144/114

Baseline characteristics

Age Continuous
Age Continuous(years)Intensive Treatment RegimenStandard Treatment RegimenTotal
Mean60.2 ± 10.0358.9 ± 9.4559.6 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)Intensive Treatment RegimenStandard Treatment RegimenTotal
Female6154115
Male5360113
08

Study locations

1 site
  • Novartis Investigative Sites
    USA, New Jersey, United States
09

References and documents

Publications

  • Solomon SD, Verma A, Desai A, Hassanein A, Izzo J, Oparil S, Lacourciere Y, Lee J, Seifu Y, Hilkert RJ, Rocha R, Pitt B; Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension. 2010 Feb;55(2):241-8. doi: 10.1161/HYPERTENSIONAHA.109.138529. Epub 2009 Dec 7. PubMed 19996069 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2007
First posted
Aug 31, 2007
Start
Nov 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Mar 10, 2011
Last update
Apr 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00523549
Responsible party
Sponsor
First posted
Aug 31, 2007
Start date
Nov 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Mar 10, 2011
Last update
Apr 23, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion